NxStage Medical, Inc.  

(Public, NASDAQ:NXTM)   Watch this stock  
Find more results for nxtm
-0.86 (-6.67%)
Apr 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.54 - 12.93
52 week 8.77 - 15.00
Open 12.93
Vol / Avg. 925,513.00/655,459.00
Mkt cap 737.11M
P/E     -
Div/yield     -
EPS -0.31
Shares 61.22M
Beta 0.54
Inst. own 96%
May 22, 2014
NxStage Medical, Inc. 2014 Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
May 8, 2014
Q1 2014 NxStage Medical, Inc. Earnings Release - 9:30AM EDT - Add to calendar
May 8, 2014
Q1 2014 NxStage Medical, Inc. Earnings Conference Call - 9:00AM EDT - Add to calendar
Feb 27, 2014
Q4 2013 NxStage Medical, Inc. Earnings Release
Feb 27, 2014
Q4 2013 NxStage Medical, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -7.45% -7.05%
Operating margin -6.59% -6.76%
EBITD margin - 2.68%
Return on average assets -6.79% -6.00%
Return on average equity -10.67% -9.47%
Employees 2,700 -
CDP Score - -


United States - Map
+1-978-6874700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company�s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

Officers and directors

Jeffrey H. Burbank Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Towse CPA Chief Financial Officer, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Joseph E. Turk Jr. President - North American Operations
Age: 45
Bio & Compensation  - Reuters
Winifred L. Swan JD Senior Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Thomas F. Shea Senior Vice President - Manufacturing Operations
Age: 50
Bio & Compensation  - Reuters
Todd M. Snell Senior Vice President - Quality Assurance, Regulatory & Clinical Affairs
Age: 42
Bio & Compensation  - Reuters
Kevin Hershberger Chief Accounting Officer, Vice President, Controller
Age: 48
Bio & Compensation  - Reuters
Robert G. Funari Non-Executive Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Jean K. Mixer Director
Age: 46
Bio & Compensation  - Reuters
Jay W. Shreiner Director
Age: 63
Bio & Compensation  - Reuters